ATE405260T1 - Thiazol- und oxazolderivaten als ppar modulatoren - Google Patents

Thiazol- und oxazolderivaten als ppar modulatoren

Info

Publication number
ATE405260T1
ATE405260T1 AT03702943T AT03702943T ATE405260T1 AT E405260 T1 ATE405260 T1 AT E405260T1 AT 03702943 T AT03702943 T AT 03702943T AT 03702943 T AT03702943 T AT 03702943T AT E405260 T1 ATE405260 T1 AT E405260T1
Authority
AT
Austria
Prior art keywords
thiazole
oxazole derivatives
ppar modulators
ppar
modulators
Prior art date
Application number
AT03702943T
Other languages
German (de)
English (en)
Inventor
Xue-Min Cheng
Noe Erasga
Gary F Filzen
Andrew G Geyer
Chitase Lee
Bharat K Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE405260T1 publication Critical patent/ATE405260T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03702943T 2002-03-07 2003-02-24 Thiazol- und oxazolderivaten als ppar modulatoren ATE405260T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
ATE405260T1 true ATE405260T1 (de) 2008-09-15

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702943T ATE405260T1 (de) 2002-03-07 2003-02-24 Thiazol- und oxazolderivaten als ppar modulatoren

Country Status (29)

Country Link
US (1) US20030207924A1 (enExample)
EP (1) EP1482935B1 (enExample)
JP (1) JP2005528348A (enExample)
KR (1) KR20040091693A (enExample)
AP (1) AP2004003124A0 (enExample)
AR (1) AR038881A1 (enExample)
AT (1) ATE405260T1 (enExample)
AU (1) AU2003206059A1 (enExample)
BR (1) BR0308277A (enExample)
CA (1) CA2478520A1 (enExample)
CO (1) CO5601012A2 (enExample)
DE (1) DE60323060D1 (enExample)
EA (1) EA200400943A1 (enExample)
EC (1) ECSP045285A (enExample)
ES (1) ES2310650T3 (enExample)
HN (1) HN2003000090A (enExample)
IS (1) IS7377A (enExample)
MA (1) MA27181A1 (enExample)
MX (1) MXPA04007564A (enExample)
NO (1) NO20044242L (enExample)
OA (1) OA12780A (enExample)
PA (1) PA8567801A1 (enExample)
PE (1) PE20030989A1 (enExample)
PL (1) PL372969A1 (enExample)
TN (1) TNSN04168A1 (enExample)
TW (1) TW200305403A (enExample)
UY (1) UY27695A1 (enExample)
WO (1) WO2003074050A1 (enExample)
ZA (1) ZA200406068B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
SI1638551T1 (sl) * 2003-05-19 2012-04-30 Irm Llc Imunosupresivne spojine in sestavki
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BRPI0511510A (pt) * 2004-05-25 2007-12-26 Metabolex Inc composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
RU2392274C2 (ru) * 2005-02-25 2010-06-20 Сеул Нэшнл Юниверсити Индастри Фаундейшн Тиазольные производные в качестве лигандов ppar-дельта и способ их получения
US7982050B2 (en) * 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2449618T3 (es) 2005-06-30 2014-03-20 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de PPAR-delta
EP1916234B1 (en) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルgpr40調節因子
CA2708391A1 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
CA2710477A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
AU2010347183A1 (en) * 2010-02-25 2012-09-06 Snu R&Db Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (PPAR), preparing method thereof and usage of the chemical compounds
US9487493B2 (en) 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
AU740444B2 (en) * 1996-08-19 2001-11-01 Japan Tobacco Inc. Propionic acid derivatives and use thereof
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2002050047A1 (en) * 2000-12-20 2002-06-27 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
KR20040030658A (ko) * 2001-06-07 2004-04-09 일라이 릴리 앤드 캄파니 페록시좀 증식제 활성화 수용체의 조절제

Also Published As

Publication number Publication date
ES2310650T3 (es) 2009-01-16
US20030207924A1 (en) 2003-11-06
HN2003000090A (es) 2004-05-05
PA8567801A1 (es) 2003-11-12
ECSP045285A (es) 2004-10-26
WO2003074050A1 (en) 2003-09-12
TW200305403A (en) 2003-11-01
MA27181A1 (fr) 2005-01-03
PE20030989A1 (es) 2003-11-29
AR038881A1 (es) 2005-02-02
UY27695A1 (es) 2003-10-31
MXPA04007564A (es) 2004-11-10
JP2005528348A (ja) 2005-09-22
EA200400943A1 (ru) 2005-02-24
AU2003206059A1 (en) 2003-09-16
EP1482935B1 (en) 2008-08-20
KR20040091693A (ko) 2004-10-28
IS7377A (is) 2004-07-29
BR0308277A (pt) 2004-12-28
NO20044242L (no) 2004-10-06
PL372969A1 (en) 2005-08-08
TNSN04168A1 (fr) 2007-03-12
OA12780A (en) 2006-07-07
EP1482935A1 (en) 2004-12-08
CO5601012A2 (es) 2006-01-31
ZA200406068B (en) 2005-09-06
DE60323060D1 (de) 2008-10-02
CA2478520A1 (en) 2003-09-12
AP2004003124A0 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
ATE405260T1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
NO20044245L (no) Tiazol- og oksazolderivater som modulerer PPAR-aktivitet
DE60010333D1 (de) Substituierte oxazole und thiazole derivate als hppar-alpha aktivatore
DE60329601D1 (de) Benzothiazolderivate mit beta-2-adrenorezeptor-agonistenwirkung
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
NO20025978L (no) Benzotiazol-derivater
ATE405562T1 (de) Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
CY2015036I2 (el) Νεα παραγωγα οξαζολιδινονης
ATE338041T1 (de) Thiazolderivate als phosphodiesterase iv- inhibtoren
AU2003207914A1 (en) Substituted thiazoles and oxazoles that modulate ppar activity
NO20043696L (no) Gamma-sekretaseinhibitorer
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
DE602004021688D1 (de) Pestizide (dihalopropenyl) phenylalkyl-substituierte benzoxazol- und benzothiazol-derivate
EP1605301A4 (en) MICRO-CAPSULE AND APPLICATION THEREOF
ATE497959T1 (de) Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate
NO20054674D0 (no) Benzotiazolderivatforbindelser, preperater og anvendelser
ATE444290T1 (de) Oxazolderivate von tetracyclinen
ATE330603T1 (de) Benzothiazolderivaten
ATE309242T1 (de) Benzothiazole
ATE329913T1 (de) Oxazole als mglur1 verstärker
DE60316290D1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren
EP1907381A4 (en) ANTIDIABETIC OXAZOLIDE INDIONE AND THIAZOLIDE INDIONE
EP1909789A4 (en) ANTIDIABETIC OXAZOLIDE INDIONE AND THIAZOLIDE INDIONE
DE60303525D1 (de) Optische Digitalquelle und Anwendunsgverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties